Sub C3

5. (Amended) [A] The compound [according to any of claims 1 to 3] of claim 1, wherein x is 1 or 2, and R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkylamino wherein the alkyl group is optionally substituted by halo.

6. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein R^3 is H, C_1 to C_7 alkyl or benzyl.

A1

7. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein R^5, R^6 and R^7 are independently selected from the group consisting of H, aryl(C_1 to C_3)alkyl and cycloalkyl(C_1 to C_3)alkyl, and are optionally substituted by halo.

8. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein Y is propylene, butylene, pentylene, hexylene, heptylene, octylene or nonylene.

9. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein $m+n \geq 3$.

10. (Amended) [A] The compound [according to] of claim 8, wherein $m+n \geq 3$, Z-R^2 is



and R^5 is benzyl or halobenzyl.

Please cancel claim 11 without prejudice.

12. (Amended) A compound which is degraded *in vivo* to yield [a] the compound [according to any] of [claims] claim 1 [to 10].

A2

13. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of [a] the compound [according to any] of [claims] claim 1 [to 10], and a physiologically acceptable diluent or carrier.

28. (Amended) [The use of an H_3 receptor ligand in the manufacture of a medicament for] A method of modifying H_3 receptor activity in a patient, which comprises administering to a patient in need of a modification a therapeutically effective amount of H_3 receptor ligand or a pharmaceutically acceptable salt thereof, said H_3 receptor ligand being a compound of the formula

A3



wherein

A is $(CH_2)_m$, m being from 1 to 3;

B is $(CH_2)_n$, n being from 1 to 3;

x is from 0 to 2;

R^1 is C_1 to C_{10} hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N, and up to 2 hydrogen atoms may be replaced by halogen;

R^2 is H or C_1 to C_{15} hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen;

R^3 is absent when -Y-Z-R^2 is attached to W, or is H or C_1 to C_7 hydrocarbyl when -Y-Z-R^2 is not attached to W;

W is nitrogen;

X is $-CH_2-$, -O- or $-NR^4-$, R^4 being H or C_1 to C_3 alkyl;

Y replaces a hydrogen atom on any of A, B, W and X, and is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is






or


wherein R^5, R^6 and R^7 are independently H or C_1 to C_{15} hydrocarbyl, in which up to 3 carbon atoms may be replaced by 0 or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring.